SecBot SecBot
SECBOTREPLAY Home › Report › AXSM

AXSM · Axsome Therapeutics announced FDA approval of AUVELITY for agitation…

Axsome Therapeutics, Inc. · 8-K filed Apr 30, 2026 at 17:19 ET

At the news

BULLISHIMPACT 8/10

8-K filed Apr 30, 2026 at 17:19 ET

Axsome Therapeutics announced FDA approval of AUVELITY for agitation associated with dementia due to Alzheimer's disease, a first-in-class treatment for a condition affecting up to 76% of Alzheimer's patients. This is a major label expansion for an already-approved drug (MDD), supported by Breakthrough Therapy designation and Priority Review, with a patent estate extending to at least 2043.

  • FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease on April 30, 2026.
  • AUVELITY is a first-in-class treatment targeting NMDA and sigma-1 receptors for this indication.
  • The sNDA was granted Breakthrough Therapy designation and evaluated under Priority Review.
  • Approval supported by Phase 3 ADVANCE-1 and ACCORD-2 trials showing statistically significant improvement on primary and key secondary endpoints.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access